Progenics Pharmaceuticals Inc. (PGNX) Net loss for the fourth quarter was $0.3 million or $0.01 per share, compared to net loss of $10.7 million or $0.32 per share in the 2011 period.
Fourth quarter revenue totaled $8.9 million, up $6.7 million from the 2011 period, resulting primarily from the partnering transactions. Royalty income for the quarter was $0.8 million compared to $1.3 million in the fourth quarter of 2011, reflecting stocking activity in 2011.
On average, 4 analysts polled by Thomson Reuters expected the company to report a loss of $0.31 per share on revenues of $1.16 million for the quarter. Analysts' estimates typically exclude special items.
For comments and feedback: editorial@rttnews.com